Evaluating The desired effect Of the drug Imeglimin In Patients With Polycystic Ovarian Syndrome
Phase 3
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2024/06/068921
- Lead Sponsor
- Riya Sharma self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Polycystic ovarian syndrome diagnosed patient with BMI = 25 kg/m2
-Patients willing to give informed consent.
Exclusion Criteria
-History of allergic reactions attributed to compounds of similar chemical or biologic composition of metformin or imeglimin
-Patients with history renal dysfunction (documented in biochemical test), acute / chronic metabolic acidosis, congestive cardiac failure needing drug treatment, lactic acidosis
-Patients on drug known to have significant drug-drug interactions either metformin or imeglimin
-Pregnant females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method